Comprehensive phenotyping of human peripheral blood B lymphocytes in healthy conditions

Rita Carsetti1,2 | Sara Terreri1 | Maria Giulia Conti3,4 | Ane Fernandez Salinas1,4 | Francesco Corrente2 | Claudia Capponi2 | Christian Albano1 | Eva Piano Mortari1

1Diagnostic Immunology Research Unit, Multimodal Medicine Research Area, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
2Microbiology and Diagnostic Immunology Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy
3Department of Maternal and Child Health, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
4Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

Abstract
The B cell compartment provides innate and adaptive immune defenses against pathogens. Different B cell subsets, reflecting the maturation stages of B cells, have non-interchangeable functions and roles in innate and adaptive immune responses. In this review, we provide an overview of the B cell subsets present in peripheral blood of healthy individuals. A specific gating strategy is also described to clearly and univocally identify B cell subsets based on their phenotypic traits by flow cytometric analysis.

KEYWORDS
B cell subsets, flow cytometry, human B cells, phenotyping

1 | B CELLS IDENTITY CARD

B cells have the function of producing antibodies for protection against infectious diseases. Protective antibodies are highly specific for the antigen that they recognize and are produced at the end of a complex differentiation pathway that requires weeks. Whereas the early phases of the development of the B lineage occur in the bone marrow, the several types of B cells detected in the peripheral blood represent the different steps of maturation mostly triggered by antigenic experience [1].

The B cell function was discovered in 1960 by Max Cooper who demonstrated that the production of antibody was completely depleted in irradiated chickens after surgical removal of the primary site of B-cell development in birds, named the Bursa of Fabricius [2], hence the name B cells.

The B-cell development occurs in steps, that are tightly controlled by the expression and function of the B-cell receptor (BCR). In the bone marrow, the B-lineage includes phenotypically distinct cell types in their different developmental stages. The success of the stepwise rearrangement of the Heavy and Light Chain is indispensable for the progression along the early phases of the developmental pathway and for the exit to the periphery. B cells emigrate from the bone marrow as transitional B cells when they express a functional BCR, composed of membrane-bound antibody, capable of recognizing the antigen, associated to the B-cell signaling module represented by the Igα-Igβ heterodimer [3, 4]. Transitional B cells expressing IgM and IgD on the cell surface represent an intermediate stages between immature and mature-naïve circulating B-cells and can be found both in the bone marrow and in the peripheral blood [5, 6] (Figure 1).

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2021 The Authors. Cytometry Part A published by Wiley Periodicals LLC. on behalf of International Society for Advancement of Cytometry.
Thanks to the phenomenon of allelic exclusion, immunoglobulin rearrangement results in the expression of a unique receptor by each B cell. Thus, every B cell has its own specificity, and the high number of possible rearrangements (>10^{12}) provides humans with a potentially infinite repertoire capable of recognizing any encountered antigen [7].

In the periphery B cells continue their development in order to fulfill their ultimate function: protection through the production of specific antibodies. Transitional B cells are short-lived and rapidly differentiate into mature-naïve B cells [8], that represent a major population in the peripheral blood and populate the primary lymphoid follicles in lymph nodes and spleen. Mature-naïve B cells continuously recirculate with the lymph and blood scrutinizing the environment in search of antigen. If they encounter the antigen that their BCR recognizes, the next phase of development initiates in the germinal centers. Activated mature-naïve B cells proliferate, introduce mutation in their immunoglobulin genes and are selected for their affinity to the antigen [9]. Only high-affinity B cells become either memory B cells or plasma cells [10, 11] (Figure 1). An alternative T- and germinal center-independent pathway leads to the generation of innate/IgM memory B cells in the spleen (Aranburu et al.[12] and see below).

The different types of B cells in peripheral blood can be distinguished by the combined expression of few clusters of differentiation (CD) markers.

In the adult peripheral blood, B cells account for ~10% of the total lymphocytes. The identification of the different B-cell type has been addressed by several research groups during the last years. The usage of different markers and classifications has led to a controversial terminology. We propose a simple nine-color staining (Table 1) to define B-cell populations with different functions in healthy donors. Among circulating CD19^{pos} B-cells we can identify six major populations: transitional, mature-naïve, memory, atypical memory, activated B cells, and plasmablasts (Figure 2 and Tables 1 and 2).

CD24^{bright}CD38^{bright} B cells in the blood correspond to transitional B cells (Figure 2, in red); they represent the most abundant
populations in the newborns and decrease to ~3% of total B cells in adults [13]. CD24^bright^CD38^bright^ transitional B cells coexpress high levels of IgM and IgD (IgM^bright^IgD^bright^). CD21, CD23 (not shown), and L-selectin (not shown) are also expressed in transitional B cells [5]. CD21 expression differentiates transitional B cells in two populations, CD21^bright^ and CD21^dim^ (Figure 2, in red). CD21^dim^ have been called Transitional 1 (T1) and are the most recent bone marrow emigrant. They still express the marker CD10, which is present in all developing B-cell in the bone marrow [6]. T1 develop into CD21^bright^ T2 cells, a population increased in autoimmune disease [14].

The two largest B-cell subsets found in the peripheral blood are mature-naive and memory B cells that can be identified by the expression of CD24 and CD27. Mature-naive B cells are CD24^pos^CD27^neg^ (Figure 2, in light blue) and correspond to the circulating B cells that migrate through the lymphoid follicles. If they are activated by the antigen, mature-naive B cells, in collaboration with T cells and dendritic cells, become the major actors of the adaptive immune response [15].

In healthy adults, 30%–50% of the B cells are CD24^bright^CD27^pos^ CD21^pos^ memory B cells (Figure 2, in blue). This population includes IgM memory B cells, expressing IgM and IgD, and IgD^neg^ that includes switched memory B cells, carrying immunoglobulins of different isotypes, and IgM-only memory B cells (Figure 2, in green). Most of the switched memory B cells express IgG (~2/3; Figure 2) and IgA (1/3) [16]. A subset of IgM-only memory B cells has also been described [17] (Figure 2).

We recently demonstrated that CD27^pos^ memory B cells can be divided in CD27^dim^ and CD27^bright^ memory B cells [18] (Figure 2). The CD27^dim^ memory B cells are the precursor of the CD27^bright^ subset. The two populations are related but have distinct molecular signatures and functions. CD27^dim^ are mostly of IgM isotype, whereas the majority of CD27^bright^ memory B cells express switched isotypes [18].

Somatic mutations indicating antigen selection are rare in the CD27^dim^ population and increase at the CD27^bright^ stage. The proportions of CD27^dim^ and CD27^bright^ change during life. CD27^bright^ MBCs become detectable at 3–4 years of age, increase to a median value of 13% of total B cells in peripheral blood at 6–9 years of age, represent the 23% (median value) of B cells in adults and reach 38% (median value) of total B cells in the elderly. CD27^dim^ memory B cells, which are the major population in children, are a minority in adults and rare in older individuals [18].

IgM memory B cells (IgM^pos^IgD^pos^CD27^pos^) are a heterogeneous population [19, 20] composed by innate memory B cells [12] and IgM memory B cells that have been remodeled in the germinal centers, where they acquired somatic mutations [12, 21, 22, 23].

Innate or natural memory B cells develop in the absence of germinal centers and T cells [12, 24], generate extra-follicular, T-independent responses, and produce natural antibodies [15, 25]. IgM memory B cells act as a first line of defense against infections [12, 15] whereas switched memory B cells embody the highly specific adaptive memory. We have shown that innate IgM memory B cells can be remodeled and acquire somatic mutations in the germinal centers thus participating to the adaptive immune response [12].

It has been shown that memory B cells, IgM and switched, are stored in the spleen, but only IgM memory B cells are significantly reduced in both asplenic and splenectomized patients [26, 27]. Due to their origin, function, and location in the spleen, IgM memory B cells have been considered the human equivalent of murine marginal zone or B-1 B cells [28–30].

IgM memory B cells are the first population of memory B cells that develop after birth. Remodeled IgM memory and switched memory B cells number increases slowly in infants [13]. The presence in the blood of switched memory B cells is an indicator of a perfectly functional germinal center reaction [12]. The immunoglobulins expressed by switched memory B cells are always more mutated than those of IgM memory B cells, indicating their role as highly specialized B cells for antigen recognition [12].

Recently, two subsets of IgM memory B cells have been described: IgM^H^ and IgM^L^ B cells [30]. IgM^H^ B cells have similarities with the previously described marginal zone B cells that have been remodeled through the germinal centers [12]. They have higher expression of CD27 and are more mutated compared to IgM^L^. Based on our results [18], IgM^H^ memory B cells coincide with remodeled

### TABLE 1

| Cluster of differentiation expressed on the different B-cell populations | Transitional | Mature-Naive | Memory | Plasma blasts | Atypical memory | Activated memory |
|---|---|---|---|---|---|---|
| CD45 | ++ | ++ | ++ | ++ | ++ | ++ |
| CD19 | ++ | ++ | ++ | ++ | ++ | ++ |
| CD24 | +++ | ++ | +++ | – | –/+ | + and ++ |
| CD21 | + and ++ | ++ | ++ | + | – | – |
| CD27 | – | – | + and +++ | +++ | – | ++ |
| CD38 | +++ | + | – | +++ | – | – |

| Igs | IgM + IgD- | IgM + IgD+ | IgM + IgD+ | IgG+ Staining | IgM + IgD+ | IgM + IgD+ |
|---|---|---|---|---|---|---|
| IgG+ | Intracellular | IgM + IgD+ | IgM + IgD+ |
| IgA+ | IgG+ | IgG+ |
| IgM only | IgG+ | IgM only |
| IgE+ | IgG+ | IgG+ |
FIGURE 2  Total blood of adult (A), 2 days old (B), and 2 months old infant (C) stained with antibodies against CD19, CD24, CD27, CD38, IgM, IgG, IgD, and CD21. Live cells were identified based on FSC/SSC lympho-monocyte gate and then selected as CD45<sup>pos</sup>CD19<sup>pos</sup> B cells. We identified transitional (CD24<sup>pos</sup>CD38<sup>bright</sup>) and plasmablasts (CD24<sup>pos</sup>CD38<sup>bright</sup>). We showed IgM, IgD, and CD21 expression in transitional B cells (CD21<sup>dull</sup> and CD21<sup>bright</sup>). In not transitional/not plasmablasts population, we discriminated mature-naive (CD24<sup>neg</sup>CD21<sup>pos</sup>), memory (CD24<sup>neg</sup>CD27<sup>pos</sup>CD21<sup>pos</sup>), atypical memory (CD21<sup>neg</sup>CD27<sup>neg</sup>), and activated B cells (CD21<sup>neg</sup>CD27<sup>pos</sup>). CD27<sup>pos</sup> memory B cells can be also divided into CD27<sup>dull</sup> and CD27<sup>bright</sup> based on CD27 expression. In the CD27<sup>pos</sup> memory B-cell population, we showed IgD<sup>pos</sup> and IgD<sup>neg</sup> memory B cells. IgD<sup>neg</sup> memory B cells were further divided into IgG<sup>pos</sup>, IgG<sup>neg</sup>IgM<sup>neg</sup> (that are mostly IgA<sup>pos</sup>), and IgM-only. Among atypical memory B cells, IgM and IgD expression identify different subtypes [Color figure can be viewed at wileyonlinelibrary.com]
|                | Transitional | Mature-Naive | Memory | Plasmablasts | Atypical memory | Activated memory | Bibliography                  |
|----------------|--------------|--------------|--------|--------------|----------------|------------------|------------------------------|
| **CD10**       | +/-          | -            | -      | -            | -              | -                | Carrion et al. [6]           |
| **CD11c**      | -            | +/-          | +/-    | +            | +              | +                | Golinski et al. [51, 52]     |
| **CD20**       | +            | +            | +      | +            | +              | +                | Pavlasova and Mraz [53]      |
| **CD22**       | ++           | +            | +      | +            | +              | +                | Martin et al. [8, 54]        |
| **CD23**       | +++          | ++           | +      | +            | +/-            | -                | Grimsholm et al. [18, 31, 47, 48] |
| **CD40**       | +            | +            | +      | -            | +/-            | +                | Ubillos et al. [43, 52, 55] |
| **CD44**       | ++           | +            | +      | -            | +/-            | -                | Martin et al. [8, 56–58]    |
| **CD55**       | +            | +            | +      | +            | +              | +                | Pascual et al. [57, 59–61]   |
| **CD62L**      | +/-          | +            | +      | +/-          | +/-            | +                | Caraux et al. [31, 59, 62]   |
| **CD63**       | +/-          | +/-          | +/-    | +            | +              | +                | Holla et al. [59, 63, 64]    |
| **CD72**       | +            | ++           | +      | -            | +              | +                | Glass et al. [56, 59, 65]    |
| **CD80**       | -            | -            | +      | -            | +              | +                | Sanz et al. [47, 62, 66]     |
| **CD84**       | ++           | +/-          | ++    | -            | +              | +                | Tangye et al. [67]           |
| **CD86**       | +/-          | +/-          | +      | +/-          | +              | +                | Sanz et al. [47, 52, 59]     |
| **CD95**       | +            | -            | ++    | +            | ++             | ++               | Grimsholm et al. [18, 47, 52, 56, 59, 62, 66] |
| **CD138**      | -            | -            | -      | +/-          | -              | -                | Caraux et al. [31]           |
| **CD151**      | +/-          | +/-          | ++    | +            | +              | +                | Holla et al. [59, 64]        |
| **CD200**      | ++           | +            |        |              |                |                  | Grimsholm et al. [18]        |
| **BAFF receptor** | ++       | +            | +      | -            | +/-            | +                | Smulski et al. [68]          |
| **β7 integrin** |              |              |        |              |                |                  | Caraux et al. [31, 59]       |
| **FCGR2B**     | ++           | ++           | ++    | +            | ++             | +                | Holla et al. [59, 69]        |
| **FCRL4**      | +            | +            | +      |              |                |                  | Li et al. [70]               |
| **TACI**       | +            | -            | +      | +            |                |                  | Cuss et al. [62]             |
| **TCL1**       | +++          | +            | +      |              |                |                  | Grimsholm et al. [18]        |
| **TLR1**       | ++           | +            | +      |              |                |                  | Grimsholm et al. [18, 71]    |
| **TLR2**       | +            | +            | +++   |              |                |                  | Grimsholm et al. [18, 71]    |
| **TLR3**       | +/-          | +/-          | +      |              |                |                  | Meyer-Bahlburg and Rawlings [71] |
| **TLR4**       | +            | +            | +      |              |                |                  | Grimsholm et al. [18, 71]    |
| **TLR5**       | +/-          | +/-          | +      |              |                |                  | Meyer-Bahlburg and Rawlings [71] |
| **TLR6**       | +            | +            | +++   |              |                |                  | Meyer-Bahlburg and Rawlings [71] |
| **TLR7**       | +            | +            | +      |              |                |                  | Meyer-Bahlburg and Rawlings [71] |
| **TLR8**       | +/-          | +/-          | +      |              |                |                  | Meyer-Bahlburg and Rawlings [71] |
| **TLR9**       | +++          | +            | +++   |              |                |                  | Meyer-Bahlburg and Rawlings [26, 71] |
| **TLR11**      | +            | +            |        |              |                |                  | Meyer-Bahlburg and Rawlings [71] |
| **CXCR3**      | +            | ++           | ++    | +            | ++             |                  | Grimsholm et al. [18, 38, 52] |
| **CXCR4**      | +            | ++           | +      | -            |              |                  | Grimsholm et al. [18, 31, 38, 62] |
| **CXCR5**      | ++           | ++           | +      | -            |              |                  | Wang et al. [38, 52, 59, 62] |
| **CCR6**       | +            | ++           |        |              |                |                  | Grimsholm et al. [18, 72]    |
| **CCR7**       | +            | +            |        |              |                |                  | Grimsholm et al. [18, 38, 59] |
| **ACKR3**      | +            | ++           |        |              |                |                  | Grimsholm et al. [18]        |
| **CCR9**       | +            | ++           |        |              |                |                  | Grimsholm et al. [18, 38]    |
| **CCR10**      | +            | +++          |        |              |                |                  | Caraux et al. [31]           |
| **IL2R**       | +            | +            | +      |              |                |                  | Grimsholm et al. [18, 38]    |
| **IL4R**       | ++           | +            | +      |              |                |                  | Grimsholm et al. [18, 38]    |

(Continues)
IgM memory B cells that belong to the CD27bright pool. IgM⁺ memory B cells have few somatic mutations and most likely overlap with the CD27dim innate memory B cells.

Plasmablasts represent ~3%–5% of CD19⁺ B cells in the peripheral blood of healthy adults. They are defined as CD24⁻/CD27bright CD38bright (Figure 2, in pink) and down-regulate CD20 expression, which, in contrast, is expressed by all other B-cells in the periphery. Circulating plasmablasts can be further differentiated by the expression of CD138. CD138⁺ plasmablasts represent a more mature stage and are characterized by the absence of surface immunoglobulin, lower CD45 expression, and higher amounts of cytoplasmic immunoglobulin [31]. Plasmablasts are differentiated B cells that provide protective immunity thanks to the continuous secretion of antibodies. Plasmablasts are precursor cells of short- and long-lived plasma cells which are the terminally differentiated elements of the B lineage [32]. Normally, plasma cells are not found in the circulation; all antibody-secreting cells in the blood en route to, for example, the bone marrow, are plasmablasts and are still considered as a proliferating fraction of antibody-secreting cells.

Plasmablasts have been extensively studied in the context of the response to influenza virus vaccination and infection. In the course of this response, another group of B cells was identified, the activated memory B cells. These cells have been found to be different from plasmablasts from the transcriptional point of view and still committed to the memory lineage [33]. Activated memory B cells are identified as CD27⁺CD21⁰ (Figure 2, in black) and can be either IgG⁺ or IgM⁺/IgD⁺. Following influenza vaccination, hemagglutinin (HA)-reactive clones are shared between activated memory B cells and transitional, mature-naive, and memory B cells can be identified in both the CD5⁺ and CD5⁻ gate. CD5 can be useful only to identify plasmablasts. When B cells are gated as CD19⁺CD5⁺ or as CD19⁺CD5⁻, plasmablasts can be found exclusively in the CD19⁺CD5⁺ gate and are absent in the CD19⁺CD5⁻ gate.

Regulatory B cells (Bregs) were originally described as transitional B cells able to produce IL-10 [50]. Later, it has been demonstrated that the capacity to secrete IL-10 can be acquired by different B cell populations depending on the culture conditions. Thus, Bregs do not have a defined phenotype but represent a functional stage with the immune-modulatory activity. A reliable method to discriminate Bregs is to perform an intracellular staining for IL-10 following an in-vitro stimulation [47].

### 2 | IDENTIFICATION OF B-CELL SUBSETS IN PERIPHERAL BLOOD OF HEALTHY DONORS BY FLOW CYTOMETRY

The cytometric analysis of the B cell surface markers is the easiest way to segregate all the above-described subsets. This analysis should be always preceded by a proper gating strategy, in order to identify living cells and exclude nonviable cells and doublets (Figure 2).

To correctly detect the different B cell populations, it is necessary to stain an adequate number of cells and use the right concentration of antibodies. An optimal antibody concentration should be established via antibody titration assays.

An appropriate selection of the best-performing clones of monoclonal antibodies and most appropriate fluorescence for each marker is of primary importance for the correct phenotypic identification of the different B-cell subsets in the peripheral blood. The choice of the brightness of the fluorochrome is particularly important when within the same B-cell population, cells may express low or high amount of a certain marker. For example, in order to discriminate between CD27ʰ and CD27ᵇ B cells we used anti-CD27 labeled with a fluorochrome with a very bright (e.g., PE) or bright (APC) fluorescence index. On the other side, we used a very dim fluorophore for CD45 (V-500) because of its homogenous expression on all B cells.

It is essential to minimize the time between blood collection in the clinic and running stained samples on the flow cytometer. We normally process the blood within maximum 24 h from collection to ensure a reliable quantification of the B-cell populations.

In order to achieve high level of standardization, reagents for B-cell multicolor panel are used in a dried format (BD Bioscience, see Table 3). Bulk lysing is performed to lyse the entire blood sample to be stained. Briefly, 500 μL of fresh total peripheral blood (EDTA) are...
Incubated for 10 min at room temperature with 9.5 mL of the lysing solution Pharm Lyse (1 ×; BD Biosciences) to remove red blood cells. Afterwards, cells are washed twice with 10 mL of phosphate-buffered saline (PBS) containing 1% of bovine serum albumin (BSA). Our staining is performed on whole blood following red blood cell lysis. In the plasma, IgG antibodies are present in high concentration. The two washing steps after lysis are essential because they wash-off the free IgGs that, by sequestering the labeled anti-IgG antibody, prevent the identification of memory B cells expressing IgG on the surface. Cells are resuspended in 200 μL of PBS and added to a B-Cell lysis tube (BD Bioscience). CD21 BV605 is added as drop-in. After 20 min incubation at room temperature in the dark, the samples are washed in PBS 1% BSA and finally resuspended in 300 μL of PBS 1% BSA. Flow cytometric data are acquired on a BD FACSLyric™ cytometer (BD Biosciences) and analyzed by FlowJo ver. 10.7 (Becton, Dickinson & Company) (See supporting informations).

In Figure 2 It is shown an example of a B cells staining in an adult control (A), and in a newborn at 48 h after delivery (B) and after 2 months of life (C). In the staining performed in the adult we can observe all the B cells described above and distributed in a normal way (Figure 2A). On the contrary, at 2 days of life B cells are essentially composed by transitional cells, a few mature B cells and very few memory B cells that are all of the IgM isotype (Figure 2B). At 2 days of life B cells are essentially composed by transitional cells, a few mature B cells and very few memory B cells that are all of the IgM isotype (Figure 2B). At 2 months of age, an expansion in different B cell populations can be detected. In particular, mature B cells, plasmablasts, and memory B cells tend to increase (Figure 2C).

The distribution of the different B cell populations significantly changes over the course of life [13]. In the first years of life, the B cell populations with the highest frequency are transitional B cells and memory cells of the IgM type. Thereafter the transitional B cells are reduced and the switched memory B cells increase [12]. Aging is associated with an increase of memory and aMBCs. Knowing the normal distribution of B cell populations based on age, allow to understand whether the variation observed by flow cytometry is associated with age or a disease state.

A correct staining allows to identify the different B-cell populations and may be of extreme importance and utility in the diagnosis of diseases associated with B cells, as discussed in the accompanied paper.

**TABLE 3** Antibodies used for the staining of the peripheral blood and the identification of the B-cell population

| Fluorochrome | Clone      |
|--------------|------------|
| CD45         | V500-C     | 2D1       |
| CD19         | PE-Cy7     | SJ25C1    |
| CD24         | PE         | ML5       |
| CD27         | APC        | L128      |
| CD38         | PerCP-Cy5.5| HIT2      |
| CD21         | BV605      | B-ly4     |
| IgM          | FITC       | G20-127   |
| IgG          | APC-H7     | G18-145   |
| IgD          | V450       | IA6-2     |

**AUTHOR CONTRIBUTIONS**

Writing—original draft: Rita Carsetti, Eva Piano Mortari, and Maria Giulia Conti. Writing—review and editing: Rita Carsetti, Eva Piano Mortari, Sara Terreri, Maria Giulia Conti, and Francesco Corrente. Methodology: Francesco Corrente, Claudia Capponi, Ane Fernandez Salinas, and Christian Albano. Formal analysis: Eva Piano Mortari, Claudia Capponi, Francesco Corrente, and Ane Fernandez Salinas. Funding acquisition: Rita Carsetti. Supervision: Rita Carsetti.

**PEER REVIEW**

The peer review history for this article is available at https://publons.com/publon/10.1002/cyto.a.24507.

**REFERENCES**

1. Carsetti R. The development of B cells in the bone marrow is controlled by the balance between cell-autonomous mechanisms and signals from the microenvironment. J Exp Med. 2000;191:5–8.
2. Ribatti D, Crivellato E, Vacca A. The contribution of Bruce Glick to the definition of the role played by the bursa of Fabricius in the development of the B cell lineage. Clin Exp Immunol. 2006;145:1–4.
3. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001;19:595–621.
4. Vale AM, Kearney JF, Nobrega A, Schroeder HW. Chapter 7—development and function of B cell subsets. In: Alt FW, Honjo T, Radbruch A, editors. Reth MBT-MB of BC. 2nd ed. London: Academic Press; 2015. p. 99–119.
5. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mice and man. Immunol Rev. 2004;197:179–91.
6. Carrozzi C, Guérin E, Gachard N, Le Guayder A, Giraud S, Feuillard J. Adult bone marrow three-dimensional phenotypic landscape of B-cell differentiation. Cyto B Clin Cytom. 2019;96:30–8.
7. Murphy KM, Travers P, Walport M. Janeway Immunologie. 2009. p. 1119.
8. Martin VG, Wu Y-CB, Townsend CL, Lu GHC, O’Hare JS, Mozelka A, et al. Transitional B cells in early human B cell development—time to revisit the paradigm? Front Immunol. 2016;7:546.
9. Janeway CA Jr, Travers P, Walport M, et al. The immune system in health and disease. B-cell activation by armed helper T cells. Garland science, 5th ed; 2001. New York: Garland Science.
10. Palm A-KE, Henry C. Remembrance of things past: long-term B cell Memory after infection and vaccination. Front Immunol. 2019;10:1787.
11. Viant C, Weymar GHJ, Escolano A, Chen S, Hartweger H, Cipolla M, et al. Antibody affinity shapes the choice between memory and germinal center B cell fates. Cell. 2020;183:1298–1311.e11.
12. Aranburu A, Piano Mortari E, Baban A, Giorda E, Cascioli S, Marcellini V, et al. Human B-cell memory is shaped by age- and tissue-specific T-independent and GC-dependent events. Eur J Immunol. 2017;47:327–44.
13. Blanco E, Pérez-Andrés M, Arriba-Méndez S, Contreras-Sanfeliciano T, Criado I, Pelak O, et al. Age-associated distribution of normal B-cell and plasma cell subsets in peripheral blood. J Allergy Clin Immunol. 2018;141(6):2206–2219.e16.
14. Zhou Y, Zhang Y, Han J, Yang M, Zhu J, Jin T. Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases. J Transl Med. 2020;18:131.
15. Capolunghi F, Cascioli S, Giorda E, Rosado MM, Plebani A, Auriti C, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. Journal of immunology. 2008;180:800–8.
16. Carsetti R, Zaffina S, Piano Mortari E, Terreri S, Corrente F, Capponi C, et al. Different innate and adaptive immune responses to
SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol. 2020;11(1):610300.

17. Bagnara D, Squillario M, Kipling D, Mora T, Walczak AM, Da Silva L, et al. A reassessment of IgM memory subsets in humans. J immunol. 2015;195(8):3716–24.

18. Grimsholm O, Plano Mortari E, Davydov AN, Shugay M, Obraztsova AS, Bocci C, et al. The interplay between CD27dull and CD27bright B cells ensures the flexibility, stability, and resilience of human B cell memory. Cell Rep. 2020;30(9):2963–77.e6.

19. Seifert M, Przekopowicz M, Taudien S, Lollies A, Körkel S, et al. Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions. Proc Natl Acad Sci. 2015;112:E546–55.

20. Berkowska MA, Driessen GJA, Bikos V, Grosserichter-Wagener C, Grosserichter-Bikos V, et al. Human B cells memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood. 2011;118:2150–8.

21. Budeus B, Schweigle de Reynoso S, Przekopowicz M, Hoffmann D, Seifert M, Küppers R. Complexity of the human memory B-cell compartment is determined by the versatility of clonal diversification in germinal centers. Proc Natl Acad Sci. 2015;112:E5281–9.

22. Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, et al. Human B cell subsets in human health and disease. Cell Immunol. 2016;139(9):770–8.

23. Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Cardeti R. Why do we need IgM memory B cells? Immunol Lett. 2013;152(2):114–20.

24. Aranburu A, Ceccarelli S, Giorda E, Lasorrella R, Ballatore G, Carsetti R, TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. Journal of immunology. 2010;185:7293–301.

25. Piano Mortari E, Baban A, Cantarutti N, Bocci C, Adorisio R, Carsetti R. Human b and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138 plasma cells. Haematologica. 2010;95:1016

26. Elstetter F, Weller S, Reynaud C-A, Human marginal zone B cells. Annu Rev Immunol. 2009;27:267–85.

27. Kruetzmann S, Rosado MM, Weber H, Gemming U, Tournilhac O, Peter H-H, et al. Human immunoglobulin M memory B Cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med. 2003;197:939–45.

28. Dascatoire M, Weller S, Irtan S, Sarnacki S, Feuillard J, Storck S, et al. Identification of a human splenic marginal zone B cell precursor with NOTCH4-dependent differentiation properties. J Exp Med. 2014;211:987–1000.

29. Weiß J-C, Weller S, Reynaud C-A. Human marginal zone B cells. Annu Rev Immunol. 2009;27:267–85.

30. Seifert M, Küppers R. Human memory B cells. Leukemia. 2016;30:2283–92.

31. Bautista D, Vásquez C, Ayala-Ramírez P, Téllez-Sosa J, Godoy-Lozano E, Martínez-Barnetche J, et al. Differential expression of IgM and IgD discriminates two subpopulations of human circulating IgM+IgD+CD27+B cells that differ phenotypically, functionally, and genetically. Front Immunol. 2020;11:736.

32. Caraux A, Klein B, Paiva B, Brett C, Schnitz A, Fuhler GM, et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138 plasma cells. Haematologica. 2010;95:1016

33. Radbruch A, Muehlenhaus G, Luger EO, Inamine A, Smith KG, Dörner T, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006;6:741–50.

34. Ellebedy AH, Jackson KJL, Kissick HT, Nakaya HI, Davis CW, Roskin KM, et al. Defining antigen-specific plasmaablast and memory B cell subsets in human blood after viral infection or vaccination. Nat Immunol. 2016;17:10):1226–34.

35. Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traore B, et al. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol. 2009;183:2176–82.
54. Onodera T, Poe JC, Tedder TF, Tsubata T. CD22 regulates time course of both B cell division and antibody response. J Immunol. 2008;180:907.

55. Lee BO, Moyron-Quiroz J, Rangel-Moreno J, Kusser KL, Hartson L, Sprague F, et al. CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses. J Immunol. 2008;180:907.

56. Glass DR, Tsai AG, Oliveria JP, Hartmann FJ, Kimmey SC, Calderon AA, et al. An integrated multi-omic single-cell atlas of human B cell identity. Immunity. 2020;53:217–232.e5.

57. Pascual V, Liu Y-J, Magalski A, de Bouteiller O, Banchereau J, Capra JD. Analysis of somatic mutation in five B cell subsets of human tonsil. 1994. 329–339

58. Brynjolfsson SF, Persson Berg L, Olsen Ekerhult T, Rimkute I, Wick M-J, Mårtensson I-L, et al. Long-lived plasma cells in mice and men. Front Immunol. 2018;9:2673.

59. Holla P, Dizon B, Ambegaonkar AA, Rogel N, Goldschmidt E, Boddapati AK, et al. Shared transcriptional profiles of atypical B cells suggest common drivers of expansion and function in malaria, HIV, and autoimmunity. Sci Adv. 2021;7(22):eabc5410.

60. Alcindor T, Kimlinger T, Witzig TE. High expression of CD59 and CD55 on benign and malignant plasma cells. Leuk Lymphoma. 2006;47:919–21.

61. Dernstedt A, Leidig J, Holm A, Kerkman PF, Mjösberg J, Ahlm C, et al. Regulation of decay accelerating factor primes human germinal center B cells for phagocytosis. Front Immunol. 2021;11:3261.

62. Li H, Dement-Brown J, Liao PJ, Mazo F, Kraus Z, et al. FC receptor-like 4 and 5 define human atypical memory B cells. J Immunol. 2008;180:1480.

63. Barrena S, Almeida J, Yunta M, López A, Fernández-Mosteirín N, Giralt M, et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia. 2005;19:1376–83.

64. Zou F, Wang X, Han X, Rothschild G, Zheng SG, Basu U, et al. Expression and function of Tetraspanins and their interacting Partners in B cells. Front Immunol. 2018;9:1606.

65. Ryu M, Hao Y, Li Y, Lyu C, Liu W, Li H, et al. Upregulation of CD72 expression on CD19+CD27+ memory B cells by CD40L in primary immune thrombocytopenia. Br J Haematol. 2017;178:308–18.

66. Ubillos I, Campo JJ, Requena P, Ome-Kaius M, Hanieh S, Rose H, et al. Corrigendum: chronic exposure to malaria is associated with inhibitory and activation markers on atypical Memory B cells and marginal zone-like B cells. Front Immunol. 2019;10:2427.

67. Tangye SG, Weerdt BCM v d, Avery DT, Hodgkin PD. CD84 is up-regulated on a major population of human memory B cells and recruits the SH2 domain containing proteins SAP and EAT-2. Europ J Immunol. 2002;32:1640–9.

68. Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival. Front Immunol. 2018;9:2285.

69. Karness JL, Dimasi N, Karness FG, Fleming R, Kuta E, Wilson M, et al. CD19 and CD32b differentially regulate human B cell responsiveness. J Immunol. 2014;192:1480.

70. Lin AA, Freeman AF, Nutman TB. IL-10 indirectly downregulates IL-4-induced IgE production by human B cells. ImmunoHorizons. 2018;2:398–406.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

**How to cite this article:** Carsetti R, Terreri S, Conti MG, Fernandez Salinas A, Corrente F, Capponi C, et al. Comprehensive phenotyping of human peripheral blood B lymphocytes in healthy conditions. Cytometry. 2022;101:131–9. [https://doi.org/10.1002/cyto.a.24507](https://doi.org/10.1002/cyto.a.24507)